缩写名/全名 |
LUNG CANCER
LUNG CANCER |
||||||||||||||||||||||||
ISSN号 | 0169-5002 | ||||||||||||||||||||||||
研究方向 | 医学-呼吸系统 | ||||||||||||||||||||||||
影响因子 | 2015:3.767, 2016:4.294, 2017:4.486, 2018:4.599, 2019:4.702, | ||||||||||||||||||||||||
出版国家 | NETHERLANDS | ||||||||||||||||||||||||
出版周期 | Monthly | ||||||||||||||||||||||||
年文章数 | 295 | ||||||||||||||||||||||||
出版年份 | 1985 | ||||||||||||||||||||||||
是否OA | No | ||||||||||||||||||||||||
审稿周期(仅供参考) | 一般,3-6周 来源Elsevier官网:平均5.9周 |
||||||||||||||||||||||||
录用比例 | 较难 | ||||||||||||||||||||||||
投稿链接 | http://ees.elsevier.com/lungcancer/default.asp?pg=preRegistration.asp | ||||||||||||||||||||||||
投稿官网 | http://www.journals.elsevier.com/lung-cancer/ | ||||||||||||||||||||||||
h-index | 114 | ||||||||||||||||||||||||
CiteScore |
|
||||||||||||||||||||||||
PubMed Central (PMC)链接 | http://www.ncbi.nlm.nih.gov/nlmcatalog?term=0169-5002%5BISSN%5D | ||||||||||||||||||||||||
中科院SCI期刊分区 ( 2018年新版本) |
|
||||||||||||||||||||||||
中科院SCI期刊分区 ( 2020年新版本) |
|
中国学者近期发表的论文 | |
1. | Radiomics signature: A potential and incremental predictor for EGFR mutation status in NSCLC patients, comparison with CT morphology Author: Wenting Tu, Guangyuan Sun, Li Fan, Yun Wang, Yi Xia, Yu Guan, Qiong Li, Di Zhang, Shiyuan Liu, Zhaobin Li Journal: LUNG CANCER, 2019, Vol., , DOI:10.1016/j.lungcan.2019.03.025 DOI |
2. | A molecular graded prognostic assessment (molGPA) model specific for estimating survival in lung cancer patients with leptomeningeal metastases Author: Kai Yin, Yang-Si Li, Mei-Mei Zheng, Ben-Yuan Jiang, Wen-Feng Li, Jin-Ji Yang, Hai-Yan Tu, Qing Zhou, Wen-Zhao Zhong, Xue-Ning Yang, Hua-Jun Chen, Hong-Hong Yan, Lin-Lin Li, Yi-Long Wu, Xu-Chao Zhang Journal: LUNG CANCER, 2019, Vol., , DOI:10.1016/j.lungcan.2019.03.015 DOI |
3. | Is Spread Through Air Spaces should be considered as a staging profile in future staging system? Author: Song Tieniu, Yidan Lin Journal: LUNG CANCER, 2019, Vol., , DOI:10.1016/j.lungcan.2019.02.016 DOI |
4. | Mutation tracking of a patient with EGFR-mutant lung cancer harboring de novo MET amplification: Successful treatment with gefitinib and crizotinib Author: Xuanxuan Zheng, Guowei Zhang, Peng Li, Mina Zhang, Xiangtao Yan, Xiaojuan Zhang, Jinbo Yang, Haixia Li, Xiyang Liu, Zhiyong Ma, Huijuan Wang Journal: LUNG CANCER, 2019, Vol.129, 72-74, DOI:10.1016/j.lungcan.2019.01.009 DOI |
5. | Diagnosing a solitary pulmonary nodule using multiple bronchoscopic guided technologies: A prospective randomized study Author: Liyan Bo, Congcong Li, Lei Pan, Hongwu Wang, Shiyue Li, Qiang Li, Chong Bai, Yiming Zeng, Yandong Nan, Yan Wang, Haidong Huang, Rui Zhou, Hongmei Zhou, Wen Liu, Jiayuan Sun, Zhiguang Liu, Faguang Jin Journal: LUNG CANCER, 2019, Vol.129, 48-54, DOI:10.1016/j.lungcan.2019.01.006 DOI |
6. | Identification of a novel WNK1–ROS1 fusion in a lung adenocarcinoma sensitive to crizotinib Author: Yutao Liu, Tianfeng Liu, Nan Li, Tao Wang, Pu Yue, Rui Lin Journal: LUNG CANCER, 2018, Vol., , DOI:10.1016/j.lungcan.2018.12.011 DOI |
7. | Case report: Crizotinib is effective in a patient with ROS1-rearranged pulmonary inflammatory myofibroblastic tumor Author: Shijie Mai, Gang Xiong, Dingwei Diao, Wenjing Wang, Yujie Zhou, Ruijun Cai Journal: LUNG CANCER, 2018, Vol.128, 101-104, DOI:10.1016/j.lungcan.2018.12.016 DOI |
8. | Loss of T790M mutation is associated with early progression to osimertinib in Chinese patients with advanced NSCLC who are harboring EGFR T790M Author: Sha Zhao, Xuefei Li, Chao Zhao, Tao Jiang, Yijun Jia, Jinpeng Shi, Yayi He, Jiayu Li, Fei Zhou, Guanghui Gao, Wei Li, Xiaoxia Chen, Chunxia Su, Shengxiang Ren, Caicun Zhou Journal: LUNG CANCER, 2018, Vol.128, 33-39, DOI:10.1016/j.lungcan.2018.12.010 DOI |
9. | Efficacy of first-line treatment with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) alone or in combination with chemotherapy for advanced non-small cell lung cancer (NSCLC) with low-abundance mutation Author: Xiangtao Yan, Huijuan Wang, Peng Li, Guowei Zhang, Mina Zhang, Jinpo Yang, Xiaojuan Zhang, Xuanxuan Zheng, Zhiyong Ma Journal: LUNG CANCER, 2018, Vol.128, 6-12, DOI:10.1016/j.lungcan.2018.12.007 DOI |
10. | Cost-effectiveness of afatinib, gefitinib, erlotinib and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China Author: Xiaohua Gu, Qiang Zhang, Yun-Bo Chu, Yi-Yang Zhao, Yan-Jun Zhang, David Kuo, Betty Su, Bin Wu Journal: LUNG CANCER, 2018, Vol.127, 84-89, DOI:10.1016/j.lungcan.2018.11.029 DOI |
|
|